Dong Sung Bio Pharm.Co.,Ltd. (002210.KS)
KRW 5320.0
(1.92%)
KRW 5320.0
(1.92%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 36.83 Billion KRW | 11.82% |
| 2022 | 32.94 Billion KRW | 25.85% |
| 2021 | 26.17 Billion KRW | 117.34% |
| 2020 | 12.04 Billion KRW | -48.64% |
| 2019 | 23.44 Billion KRW | -42.02% |
| 2018 | 40.44 Billion KRW | 48.81% |
| 2017 | 27.17 Billion KRW | -26.87% |
| 2016 | 37.16 Billion KRW | 6.68% |
| 2015 | 34.83 Billion KRW | 5.94% |
| 2014 | 32.88 Billion KRW | 4.41% |
| 2013 | 31.49 Billion KRW | 11.76% |
| 2012 | 28.18 Billion KRW | 5.22% |
| 2011 | 26.78 Billion KRW | 5.73% |
| 2010 | 25.33 Billion KRW | -10.34% |
| 2009 | 28.25 Billion KRW | 31.32% |
| 2008 | 21.51 Billion KRW | -16.02% |
| 2007 | 25.61 Billion KRW | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | 49.89 Billion KRW | 11.03% |
| 2024 Q1 | 44.93 Billion KRW | 21.99% |
| 2023 Q4 | 36.83 Billion KRW | -4.67% |
| 2023 Q3 | 38.64 Billion KRW | 5.06% |
| 2023 FY | 36.83 Billion KRW | 11.82% |
| 2023 Q2 | 36.78 Billion KRW | 5.33% |
| 2023 Q1 | 34.91 Billion KRW | 6.0% |
| 2022 Q2 | 26.78 Billion KRW | -1.47% |
| 2022 Q1 | 27.18 Billion KRW | 3.86% |
| 2022 FY | 32.94 Billion KRW | 25.85% |
| 2022 Q4 | 32.94 Billion KRW | 1.25% |
| 2022 Q3 | 32.53 Billion KRW | 21.47% |
| 2021 Q1 | 12.64 Billion KRW | 4.96% |
| 2021 Q3 | 21.14 Billion KRW | -4.2% |
| 2021 Q4 | 26.17 Billion KRW | 23.76% |
| 2021 FY | 26.17 Billion KRW | 117.34% |
| 2021 Q2 | 22.07 Billion KRW | 74.65% |
| 2020 Q1 | 17.16 Billion KRW | -26.8% |
| 2020 FY | 12.04 Billion KRW | -48.64% |
| 2020 Q2 | 9.39 Billion KRW | -45.29% |
| 2020 Q4 | 12.04 Billion KRW | -1.44% |
| 2020 Q3 | 12.21 Billion KRW | 30.12% |
| 2019 Q2 | 21.77 Billion KRW | -43.68% |
| 2019 Q3 | 23.87 Billion KRW | 9.68% |
| 2019 Q4 | 23.44 Billion KRW | -1.8% |
| 2019 FY | 23.44 Billion KRW | -42.02% |
| 2019 Q1 | 38.65 Billion KRW | -4.41% |
| 2018 Q4 | 40.44 Billion KRW | 9.33% |
| 2018 Q1 | 28.03 Billion KRW | 3.16% |
| 2018 FY | 40.44 Billion KRW | 48.81% |
| 2018 Q2 | 36.68 Billion KRW | 30.85% |
| 2018 Q3 | 36.99 Billion KRW | 0.84% |
| 2017 Q2 | 35.03 Billion KRW | 2.61% |
| 2017 Q4 | 27.17 Billion KRW | -15.07% |
| 2017 FY | 27.17 Billion KRW | -26.87% |
| 2017 Q3 | 31.99 Billion KRW | -8.67% |
| 2017 Q1 | 34.14 Billion KRW | -8.12% |
| 2016 Q3 | 35.22 Billion KRW | -1.24% |
| 2016 Q4 | 37.16 Billion KRW | 5.49% |
| 2016 Q1 | 35.67 Billion KRW | 2.42% |
| 2016 FY | 37.16 Billion KRW | 6.68% |
| 2016 Q2 | 35.66 Billion KRW | -0.03% |
| 2015 Q1 | 34.08 Billion KRW | 3.66% |
| 2015 Q4 | 34.83 Billion KRW | -1.63% |
| 2015 Q3 | 35.41 Billion KRW | -3.44% |
| 2015 FY | 34.83 Billion KRW | 5.94% |
| 2015 Q2 | 36.67 Billion KRW | 7.59% |
| 2014 Q2 | 29.14 Billion KRW | -2.63% |
| 2014 FY | 32.88 Billion KRW | 4.41% |
| 2014 Q4 | 32.88 Billion KRW | -2.24% |
| 2014 Q3 | 33.63 Billion KRW | 15.42% |
| 2014 Q1 | 29.93 Billion KRW | -4.96% |
| 2013 Q3 | 29.31 Billion KRW | -0.87% |
| 2013 Q4 | 31.49 Billion KRW | 7.44% |
| 2013 FY | 31.49 Billion KRW | 11.76% |
| 2013 Q2 | 29.57 Billion KRW | 8.58% |
| 2013 Q1 | 27.23 Billion KRW | -3.36% |
| 2012 Q1 | 28.8 Billion KRW | 0.0% |
| 2012 FY | 28.18 Billion KRW | 5.22% |
| 2012 Q4 | 28.18 Billion KRW | -8.92% |
| 2012 Q3 | 30.94 Billion KRW | -2.43% |
| 2012 Q2 | 31.71 Billion KRW | 10.11% |
| 2011 FY | 26.78 Billion KRW | 5.73% |
| 2011 Q3 | 26.64 Billion KRW | 0.16% |
| 2011 Q2 | 26.6 Billion KRW | -6.51% |
| 2011 Q1 | 28.45 Billion KRW | 12.34% |
| 2010 Q1 | 29.76 Billion KRW | 5.35% |
| 2010 FY | 25.33 Billion KRW | -10.34% |
| 2010 Q4 | 25.33 Billion KRW | -28.56% |
| 2010 Q3 | 35.46 Billion KRW | 3.12% |
| 2010 Q2 | 34.38 Billion KRW | 15.54% |
| 2009 Q4 | 28.25 Billion KRW | 14.57% |
| 2009 FY | 28.25 Billion KRW | 31.32% |
| 2009 Q2 | 25.28 Billion KRW | 8.6% |
| 2009 Q1 | 23.27 Billion KRW | 8.19% |
| 2009 Q3 | 24.65 Billion KRW | -2.45% |
| 2008 Q1 | 19.3 Billion KRW | -24.65% |
| 2008 Q3 | 20.88 Billion KRW | -0.73% |
| 2008 FY | 21.51 Billion KRW | -16.02% |
| 2008 Q4 | 21.51 Billion KRW | 3.01% |
| 2008 Q2 | 21.04 Billion KRW | 9.0% |
| 2007 Q1 | 20.19 Billion KRW | 0.0% |
| 2007 Q3 | 19.58 Billion KRW | 9.99% |
| 2007 Q2 | 17.8 Billion KRW | -11.81% |
| 2007 FY | 25.61 Billion KRW | 0.0% |
| 2007 Q4 | 25.61 Billion KRW | 30.79% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 8.8 Billion KRW | -318.499% |
| Dong-A Socio Holdings Co., Ltd. | 572.02 Billion KRW | 93.56% |
| Ildong Holdings Co., Ltd. | 310.87 Billion KRW | 88.15% |
| HANDOK Inc. | 283.45 Billion KRW | 87.004% |
| Kukje Pharma Co., Ltd. | 20.07 Billion KRW | -83.524% |
| Yuhan Corporation | -69.18 Billion KRW | 153.244% |
| Dong-A ST Co., Ltd. | 193.95 Billion KRW | 81.007% |
| SAMSUNG PHARM. Co., LTD. | -3.68 Billion KRW | 1099.436% |
| Hanmi Pharm. Co., Ltd. | 517.88 Billion KRW | 92.887% |
| Hanall Biopharma Co.,Ltd | -32.43 Billion KRW | 213.584% |
| Ilyang Pharmaceutical Co.,Ltd | 75.67 Billion KRW | 51.321% |
| MYUNGMOON Pharm co.,Ltd | 82.52 Billion KRW | 55.36% |
| Hana Pharm Co., Ltd. | 25.1 Billion KRW | -46.713% |
| Yuyu Pharma, Inc. | 8.8 Billion KRW | -318.499% |
| Ilsung Pharmaceuticals Co., Ltd. | -159.84 Billion KRW | 123.045% |
| REYON Pharmaceutical Co., Ltd. | 200.94 Billion KRW | 81.668% |
| Aprogen pharmaceuticals,Inc. | 170.94 Billion KRW | 78.451% |
| JW Holdings Corporation | 480.68 Billion KRW | 92.337% |
| Ildong Pharmaceutical Co., Ltd. | 164.58 Billion KRW | 77.618% |
| Chong Kun Dang Pharmaceutical Corp. | 117.53 Million KRW | -31242.553% |
| JW Pharmaceutical Corporation | 154.37 Billion KRW | 76.137% |
| Shin Poong Pharm.Co.,Ltd. | 2.35 Billion KRW | -1466.668% |
| Hyundai Pharmaceutical Co., Ltd. | 23 Billion KRW | -60.152% |
| Samil Pharmaceutical Co.,Ltd | 174.97 Billion KRW | 78.947% |
| Jeil Pharmaceutical Co.,Ltd | 51.97 Billion KRW | 29.124% |
| Yuyu Pharma, Inc. | 8.8 Billion KRW | -318.499% |
| Kwang Dong Pharmaceutical Co., Ltd. | 158.29 Billion KRW | 76.729% |
| Daewoong pharmaceutical Co.,Ltd | 358.17 Billion KRW | 89.715% |
| JW Pharmaceutical Corporation | 154.37 Billion KRW | 76.137% |
| Yuhan Corporation | -69.18 Billion KRW | 153.244% |
| Jeil Pharma Holdings Inc | 135.99 Billion KRW | 72.912% |
| Yungjin Pharm. Co., Ltd. | 59.67 Billion KRW | 38.269% |
| Suheung Co., Ltd. | 429.14 Billion KRW | 91.416% |
| JW Pharmaceutical Corporation | 154.37 Billion KRW | 76.137% |
| Samjin Pharmaceuticals Co., Ltd. | 116.23 Billion KRW | 68.308% |
| Korea United Pharm Inc. | 16.42 Billion KRW | -124.275% |
| CKD Bio Corp. | 143.29 Billion KRW | 74.293% |
| Daewon Pharmaceutical Co., Ltd. | 116.06 Billion KRW | 68.262% |
| Dongwha Pharm.Co.,Ltd | -24.06 Billion KRW | 253.095% |
| Whan In Pharm Co.,Ltd. | -44.73 Billion KRW | 182.347% |
| Shin Poong Pharm.Co.,Ltd. | 2.35 Billion KRW | -1466.668% |
| Chong Kun Dang Holdings Corp. | 422.84 Billion KRW | 91.288% |
| Boryung Corporation | 187.72 Billion KRW | 80.377% |
| Bukwang Pharmaceutical Co., Ltd. | -71.84 Billion KRW | 151.277% |
| Ilyang Pharmaceutical Co.,Ltd | 75.67 Billion KRW | 51.321% |
| JW Lifescience Corporation | 26.09 Billion KRW | -41.19% |